Skip to content
Screener

Solid Biosciences Inc. SLDB Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$11.2M-15.6%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$57.3M+25.7%
Insmed logo
InsmedINSM
$6.27M+78.4%
Regenxbio logo
RegenxbioRGNX
$7.36M-8.6%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$5.03M-1.5%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$1.02M+1.6%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.4M-37.6%
Net income-$54.8M-38.8%
EPS (diluted)-$0.38+9.5%

Balance sheet

See full
Cash & equivalents$159.4M+14.7%
Total debt$20.2M-12.6%
Total equity$374.1M+44.8%
Total assets$420.6M+36.4%

Cash flow

See full
Operating cash flow-$52.6M-40.6%
CapEx$150.0K-60.2%
Free cash flow-$52.7M-39.6%

Valuation

See full
Market cap$899.62M+90.9%
Enterprise value$760.38M+114%

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-65.5%-2.5pp
Debt / equity0.1×0.0×
Current ratio13.8×+4.5×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337935

FAQ

What is Solid Biosciences Inc.'s operating lease liabilities (current)?
Solid Biosciences Inc. (SLDB) reported operating lease liabilities (current) of $2.23M in Q2 2026.
How has Solid Biosciences Inc.'s operating lease liabilities (current) changed year-over-year?
Solid Biosciences Inc.'s operating lease liabilities (current) increased by 15.0% year-over-year, from $1.94M to $2.23M.
What is the long-term trend for Solid Biosciences Inc.'s operating lease liabilities (current)?
Over 5 years (2020 to 2025), Solid Biosciences Inc.'s operating lease liabilities (current) has grown at a 1.0% compound annual growth rate (CAGR), from $2M to $2.1M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Solid Biosciences Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude